» Articles » PMID: 37663492

Substituted 1,2,4-Triazoles As Novel and Selective Inhibitors of Leukotriene Biosynthesis Targeting 5-Lipoxygenase-Activating Protein

Overview
Journal ACS Omega
Specialty Chemistry
Date 2023 Sep 4
PMID 37663492
Authors
Affiliations
Soon will be listed here.
Abstract

5-Lipoxygenase-activating protein (FLAP) is a regulator of cellular leukotriene biosynthesis, which governs the transfer of arachidonic acid (AA) to 5-lipoxygenase for efficient metabolism. Here, the synthesis and FLAP-antagonistic potential of fast synthetically accessible 1,2,4-triazole derivatives based on a previously discovered virtual screening hit compound is described. Our findings reveal that simple structural variations on 4,5-diaryl moieties and the 3-thioether side chain of the 1,2,4-triazole scaffold markedly influence the inhibitory potential, highlighting the significant chemical features necessary for FLAP antagonism. Comprehensive metabololipidomics analysis in activated FLAP-expressing human innate immune cells and human whole blood showed that the most potent analogue selectively suppressed leukotriene B formation evoked by bacterial exotoxins without affecting other branches of the AA pathway. Taken together, the 1,2,4-triazole scaffold is a novel chemical platform for the development of more potent FLAP antagonists, which warrants further exploration for their potential as a new class of anti-inflammatory agents.

Citing Articles

Search for New Compounds with Anti-Inflammatory Activity Among 1,2,4-Triazole Derivatives.

Glomb T, Minta J, Nowosadko M, Radzikowska J, Swiatek P Molecules. 2025; 29(24.

PMID: 39770124 PMC: 11677506. DOI: 10.3390/molecules29246036.

References
1.
Ho J, Lee M, Rauch C, Aznavour K, Park J, Luz J . Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP). Biochim Biophys Acta Gen Subj. 2020; 1865(2):129800. DOI: 10.1016/j.bbagen.2020.129800. View

2.
Follows R, Snowise N, Ho S, Ambery C, Smart K, McQuade B . Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study. Respir Res. 2013; 14:54. PMC: 3732081. DOI: 10.1186/1465-9921-14-54. View

3.
Gur Z, Caliskan B, Banoglu E . Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis. Eur J Med Chem. 2017; 153:34-48. DOI: 10.1016/j.ejmech.2017.07.019. View

4.
Werner M, Jordan P, Romp E, Czapka A, Rao Z, Kretzer C . Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome. FASEB J. 2019; 33(5):6140-6153. PMC: 6988863. DOI: 10.1096/fj.201802509R. View

5.
Sardella R, Levent S, Ianni F, Caliskan B, Gerstmeier J, Pergola C . Chromatographic separation and biological evaluation of benzimidazole derivative enantiomers as inhibitors of leukotriene biosynthesis. J Pharm Biomed Anal. 2013; 89:88-92. DOI: 10.1016/j.jpba.2013.10.039. View